6 Nov · 2 min

Alethio, Candi Solar, Vensum Power — $90M alle terapie, $50M al solare e €9M all’efficienza energetica — Daily News 6 novembre 2026

Alethio Therapeutics raises $90m to take preclinical ATX-011 into phase 1/2a trials, co-led by Sofinnova and RA Capital.
Candi Solar signs a $50m debt facility with Pentagreen Capital for about 400 MWp of solar and batteries in India.
Vensum Power raises €9m for power-conversion tech, targeting 2027 mass production though near-lossless claims remain unproven at scale.

Alethio Therapeutics raises $90m Series A for blood cancer drug

Funding and deals

Alethio Therapeutics. Oxford biotech developing ATX-011 against myeloproliferative neoplasms raised a $90m Series A co-led by Sofinnova Partners and RA Capital for phase 1/2a trials.
Candi Solar. Swiss firm that finances, builds and manages solar plants for businesses signed a $50m debt facility with Pentagreen Capital for about 400 MWp in India.
Vensum Power. Helsinki deeptech controlling power conversion for EV charging, storage and microgrids raised €9m Series A co-led by Lifeline Ventures, Larsen & Toubro and Eviny Ventures.